INTRODUCTION
Hepatitis C (HCV) virus infection is a major cause of chronic liver disease worldwide, up to 70% of patients develop chronic infection which, in 20% of cases, will progress to cirrhosis and finally to hepatocellular carcinoma [1] .
Indeed, HCV is not directly cytopathic, and the mechanisms by which it causes liver injury are not well established. Immune response that essentially conducted by cytokines may play an important role in the pathogenesis of HCV infection [2] .
A strong T-helper lymphocyte-cell response, characterized by the production of interleukin-2, tumor necrosis factor-alpha and interferongamma, seems to be associated with HCV clearance; however, in the context of a persistent infection, they may be responsible for liver damage [3] .
Cytokines genes are polymorphic at specific sites, and some of these mutations have been associated with inter-individual variations of cytokine expression. The Interleukin (IL)-18 gene is located on chromosome 11q22.2-q22.3 and a variety of single nucleotide polymorphisms have been detected within IL-18 gene sequence. Several of these polymorphisms, especially those located in the promoter region, may be associated with differential levels of gene transcription [4] .
IL-18 first identified as an IFN-γ inducing factor, is mainly produced by activated macrophages and Kuffer cells, and plays a strategic role in inflammation and liver injury. It exerts a proinflammatory activity by enhancing the Fas ligand and perforin-mediated T-cell and natural killer-cell cytotoxicity, stimulating Th 1 -cell development, inducing chemokines, and decreasing IL-10 expression in T cells. Besides, IL-18 increases the susceptibility of liver endothelial cells to undergo apoptosis [5] .
In chronic hepatitis C and cirrhosis, an increase in the expression of proinflammatory cytokines, in particular IL-18, has been shown, which correlates with IFN-γ production [6] .
The objective of this study was to study serum IL-18 levels in chronic HCV related liver diseases.
PATIENTS AND METHODS
This study was carried out in Tropical Medicine Department, Faculty of Medicine, Menofia University Hospitals. The study was conducted on four groups: Group I: Included twenty patients with chronic active hepatitis C were selected from patients waiting the interferon based antiviral treatment; all performed liver biopsy and showed hisopathological features of chronic active hepatitis. Group II: Included twenty patients with chronic HCV related non complicated liver cirrhosis (compensated or decompensated). Group III: Included twenty patients with complicated chronic HCV related liver cirrhosis. Group IV: Included ten healthy persons of matched age and sex as control group. After having an informed consent; each patient underwent: Detailed history taking, thorough clinical examination, laboratory investigations including liver profile tests (ALT, AST, bilirubin, serum albumin and INR), viral markers (HCV antibody, HBsAg), quantitative HCV RNA by the PCR, serum alpha-fetoprotein, imaging study (abdominal ultrasonography and triphasic CT scan for HCC patients) and measurement of serum IL-18 using ELISA kit.
Exclusion criteria:
Patients with chronic liver diseases due to any cause other than chronic HCV and patients with any disease known to affect serum level of IL-18 (chronic infection, diabetes mellitus, renal failure, coronary heart disease, other malignancies, etc) were excluded from the present study.
Statistical analysis:
Data were collected, tabulated and statistically analyzed by computer data using SPSS (Statistical Package for Social Sciences) version 15. Qualitative data were presented as number and percent. Comparison between groups was done by ChiSquare test. Quantitative data were tested for normality by Kolmogrov-Smirnov test. Normally distributed data were presented as mean ± SD. Student t-test was used to compare between two groups. F-test (One Way Anova) was used to compare between more than two groups. Pearson's correlation coefficient was used to test correlation between variables. P<0.05 was considered to be statistically significant.
RESULTS
No statistically significant differences were reported among the studied groups as regarding age and sex as shown in Table (1). There were a highly significant increases in the mean values of serum IL-18 in chronic HCV related liver cirrhosis, non complicated and complicated patients in comparison to chronic active hepatitis C patients and healthy subjects. Also, there was a highly significant increase in the mean values of serum IL-18 in complicated patients in comparison to non complicated patients as shown in Table ( 2).
It is obvious from our results that IL-18 correlates with progression of cirrhosis, where a highly significant increase in the mean values of serum IL-18 in decompensated liver cirrhosis patients was noticed when compared to compensated patients as shown in Table ( 3).
The serum IL-18 concentrations were related to the Child-Pugh severity of liver disease in cirrhotic patients as shown in Figure (1) .
The complications of liver cirrhosis do have an impact on the level of IL-18. There was a highly significant increase in the mean values of serum IL-18 in cirrhotic patients complicated by HCC followed by cirrhotic patients complicated by hepatorenal syndrome (HRS) as shown in Table  (4) . reported that the mean levels of IL-18 were significantly elevated in patients with chronic hepatitis C and HCV-related cirrhosis when compared with the normal controls.
The difference between the chronic hepatitis and cirrhotic groups was also significant. IL-18 protein production was quantified in serum samples from 50 patients in different stages of HCV infection and compared with 15 normal healthy controls. As necrosis and fibrosis are associated, independent correlations in only six patients, in whom IL-18 levels were strongly related to necroinflammation. Thus, the pathological consequences of infection mediated by IL-18 are clearly detrimental to the host.
Also, Bouzgarrou et al. [11] reported that plasma levels of IL-18 were elevated in chronic active hepatitis C patients than healthy controls, cirrhotic patients had higher levels than non cirrhotic patients and elevated in HCC patients than cirrhotic patients. Moreover, Selim et al. [12] reported that IL18 levels are elevated in chronic hepatitis C patients than in healthy subjects. IL-18 level is significantly increased with the increase in the histological stage of fibrosis, disease progression is accompanied by an increase in plasma IL-18 and strongly support the involvement of IL-18 in causing liver injury. Thus IL-18 could be used and nominated as an additional non invasive marker for monitoring the degree of liver fibrosis in chronic hepatitis C patients.
Statistical analysis revealed highly significant increase in the mean values of serum IL-18 in decompensated liver cirrhosis patients when compared to compensated patients and highly significant positive correlation between ChildPugh score and serum IL-18 level in group II patients. These results are in agreement with Urushihara et al. [13] who reported that serum level of IL-18 in patients with HCV as disease progressed from non cirrhotic to cirrhotic as well as with deterioration of cirrhosis from ChildPugh stage A to stage Child-B and then to stage Child-C, further increased IL-18 serum levels were observed. Similarity, Tilg and Diehl [14] found that plasma IL-18 levels were increased with disease progression independent of the etiology of chronic liver disease.
IL-18 mRNA expression was significantly upregulated in the peripheral blood mononuclear cells (PBMC) of cirrhotic patients when compared with other groups, while in the liver, higher levels of IL-18 transcripts were expressed in patients with chronic hepatitis C. 
CONCLUSION
Serum IL-18 level shows highly positive significant correlation with severity of liver dysfunction in HCV related liver cirrhosis. Serum IL-18 may play a role in pathogenesis of hepatic decompensation and occurrence of hepatic complications in patients with HCV related cirrhosis.
